ライフサイエンスコーパス: phenylethyl

1 1-((1R,2R)-2-Hydroxy-1-methyl-2-phenylethyl)-1-methyl-3-(4-phenoxyphenyl)u rea (1) was i

2 ely evaluated the potency of a series of new phenylethyl[1,2,4]methyltriazines which are analogues of

3 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methox

4 obenzyl)- (10l, PSB-12441, Ki 7.23 nM), N(6)-phenylethyl- (10h, PSB-12425, Ki 8.04 nM), and N(6)-benz

5 romethyl)-3H-diazirin-3-yl]benzyl-[(3)H]1-(1-phenylethyl)-1H-imidaz ole-5-carboxylate), acts as a pos

6 1-(1-(4-(3-trifluoromethyl)-3H-diazirin-3-yl)phenylethyl)-1H-imidazole-5-c arboxylate).

7 [(3)H]2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(phenylethyl)-1H-imidazole-5-carboxylate (azietomidate) a

8 D-MPAB), photoreactive analogs of 2-ethyl 1-(phenylethyl)-1H-imidazole-5-carboxylate (etomidate) and

9 e) and BzBzl-etomidate (4-benzoylbenzyl-1-(1-phenylethyl)-1H-imidazole-5-carboxylate are both potent

10 rifluoromethyl)-3H-diazirin-3-yl]benzyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate) and BzBzl-etomi

11 general anesthetic etomidate (R-(2-ethyl 1-(phenylethyl)-1H-imidazole-5-carboxylate)).

12 us anesthetic, R-(+)-etomidate (2-ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate), has been synth

13 ous general anesthetic etomidate (2-ethyl 1-(phenylethyl)-1H-imidazole-5-carboxylate), in which the 2

14 ate [2-(3-methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate] anesthetizes ta

15 pyrrole analog of etomidate, (R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate),

16 We synthesized new N-phenylethyl-1H-indole-2-carboxamides as the first SAR st

17 caftor), nitrate ion (NO3 (-) ) and N(6) -(2-phenylethyl)-2'-deoxy-ATP (d-PATP), which almost complet

18 We custom synthesized N(6)-(2-phenylethyl)-2'-deoxy-ATP (P-dATP), an analog combining

19 Interestingly, an ATP analogue, N6-(2-phenylethyl)-2'-deoxy-ATP (P-dATP), can increase the ope

20 doR antagonist radioligand [3H]-5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo [4,3-epsilon]-1,2,4-tr

21 0.03 or 0.3 mg/kg, or SCH58261 [5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[

22 ptor (A2AR)-specific antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-epsilon]-1,2,4-tri

23 tuted adenosine analogues to yield N(6)-(2''-phenylethyl)-2-[(2'' -phenylethyl)amino]adenosine (69) a

24 Using 3-deuterio-1-(1-phenylethyl)-2-methyleneaziridine, 26, we determined tha

25 1R,5R,9S)-(-)-9-hydroxy-5-(3-hydroxyphenyl-2-phenylethyl-2-azabicyclo[3.3.1]nona ne ((1R,5R,9S)-(-)-1

26 oxo)-indole-3-acetic acid (auxinole), alpha-(phenylethyl-2-oxo)-indole-3-acetic acid (PEO-IAA), and 5

27 onist, FSPTP (5-amino-7-[2-(4-fluorosulfonyl)phenylethyl]-2-(2-furyl)-pryazolo[4,3-epsilon]-1, 2,4-tr

28 lfanyl]-5,6-dihydro-4 -hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one].

29 = 51 nM, 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3- [(2-phenyl-ethyl)thio]-2H-pyran-2-one].

30 applying all couples to derivatize benzyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl amines, and t

31 entive properties of sulindac, curcumin, and phenylethyl-3-methylcaffeate (PEMC) and the tumor-promot

32 R(+)-a-(2, 3-dimethoxyphenyl)-1-[2(4-fluoro-phenylethyl)]-4-piperidine-methanol (MDL 100,907), and t

33 inazolin-4-yl]urea (VUF5574) but not by 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-

34 mimicked by several A(2A) antagonists (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-

35 d 2-chloro-5, 11-dihydro-11-ethyl-5-methyl-8-phenylethyl-6H-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-o

36 ta-linalool, 2-,3-dimethylbutyl butanoate, 2-phenylethyl acetate, 2,3-butanedione, hexanedioic acid,

37 acetate, ethyl octanoate, ethyl decanoate, 2-phenylethyl acetate, 2-phenylethanol, 2-methoxyphenol, 4

38 sed concentrations of 2-phenyl ethanol and 2-phenylethyl acetate, both associated with positive senso

39 (E)-3(6-bromopyridin-2-yl)-2-cyano-N-((S0-1-phenylethyl)acrylamide) (WP1066) is a novel analogue of

40 acid (vinegar), octanoic acid (rancid), and phenylethyl alcohol (floral).

41 mprinted juvenile salmon to the odorant beta-phenylethyl alcohol (PEA) and examined the sensitivity o

42 applied to a commercial crumb, with acetoin, phenylethyl alcohol and acetic acid as highly abundant c

43 acid, furfural, benzaldehyde, (E)-2-nonenal, phenylethyl alcohol and short-medium chain acids were fo

44 -methyl-1-propanol, 3-methyl-1-butanol and 2-phenylethyl alcohol, which decreased 68%, 80%, and 86%,

45 and Olfactory Threshold Sniffin' Sticks with phenylethyl alcohol.

46 We investigated various substituted phenylethyl, alpha-methylbenzyl, and oxazolylmethyl grou

47 -butylsulfinamide derived from (-)-(S)-alpha-phenylethyl amine, a (+)-diastereomer and a (-)-diastere

48 5-diphenylpyrrolidine and from (R)-bis((R)-1-phenylethyl)amine, and show that they lead to low activa

49 ined with dienophiles based on (R)-bis((R)-1-phenylethyl)amine.

50 eptor agonist, or with 2-[p-(2-carboxyethyl)-phenylethyl amino]-5'-N-ethyl-carboxamido-adenosine (CGS

51 R)-5-(3-(18F-fluoromethoxy)phenyl)-3-(((R)-1-phenylethyl)amino)-1-(4-(triflu oromethyl)-phenyl)pyrrol

52 Among these, 2-((1-(benzyl(2-hydroxy-2-phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)

53 t [JNJ-63533054, (S)-3-chloro-N-(2-oxo-2-((1-phenylethyl)amino)ethyl) benzamide].

54 ues to yield N(6)-(2''-phenylethyl)-2-[(2'' -phenylethyl)amino]adenosine (69) as a 30 microM inhibito

55 entyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4 -biphenylyl)methyl]propanami

56 receptor agonist), and 2-[p-(2-carboxyethyl)]phenylethyl-amino-5'-N-ethylcarboxamidoadenosine(CGS 216

57 o the selective agonist 2-[p-(2-carboxyethyl)phenylethyl-amino]-5'-N-ethylcarboxamido adenosine (CGS2

58 ion of 1 from isobutyl (3S)-3-[methyl[(1S)-1-phenylethyl]amino]butanoate (5c).

59 S)-[[(3, 5-dicarboxyphenyl)amino]carbonyl]-2-phenylethyl]amino]carbonyl]-6- [[( 1-adamantylmethyl)ami

60 de) and a 2D-structured perovskite material (phenylethyl ammonium lead bromide), which can be ascribe

61 y and selectivity at kappa receptor, and N-2-phenylethyl analogue 18 exhibited good affinity and sele

62 provement in affinity realized for the alpha-phenylethyl analogue 3, in this paper we explored the ef

63 Phenylethyl analogues had a higher binding affinity for

64 The 2-(2-pyridyl)amino-1-phenylethyl and 2-[N-methyl-N-(2-pyridyl)]aminoethyl gro

65 vided no increase in affinity relative to 2, phenylethyl and diphenylethyl substitution, as in 105 an

66 estingly, we found that the ATP analog N6-(2-phenylethyl)-ATP (P-ATP) increases G551D currents mainly

67 viously we found that the ATP analog N(6)-(2-phenylethyl)-ATP (P-ATP) potentiates the activity of G55

68 hree N6-modified ATP analogues tested, N6-(2-phenylethyl)-ATP (P-ATP) was the most potent, with a K(1

69 , and the ligand exchange time for ATP/N6-(2-phenylethyl)-ATP (P-ATP), which measures the stability o

70 2-Nitro-N-alkyl-N-(2-oxo-2-phenylethyl)benzenesulfonamide compounds are known to un

71 ation, and pKa = 21.2 for the 1,3-bis-((S)-1-phenylethyl)benzimidazolium cation.

72 howed that it can produce benzylbenzoate and phenylethyl benzoate, both present in petunia corollas,

73 alactosidase and the cell-permeant inhibitor phenylethyl beta-D-thiogalactopyranoside (PETG), determi

74 vely, and the activity was inhibited by both phenylethyl-beta-d-thiogalactopyranoside and deoxygalact

75 Enzyme inhibition assays with phenylethyl-beta-D-thiogalactoside (PETG) were also comp

76 s with the specific rates of solvolysis of 2-phenylethyl bromide and methyl tosylate show only a mode

77 hyl)amino]methyl}-2-{4-[(2-bromoacetyl)amino]phenylethyl}(ca rboxymethyl)amino]acetic acid, iron(III)

78 The highest affinities were obtained using phenylethyl carbamate and phenylbutyrylamide functionali

79 c serine protease inhibitor L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK) did not inhibit t

80 ), a NFkappaB inhibitor, or l-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK), a serine proteas

81 y described N-benzyl derivative (3) to the N-phenylethyl derivative 4 also showed reduced potency (<

82 photo-Claisen reactions of 1-naphthyl (R)-1-phenylethyl ether ((R)-2), in combination with photo-Fri

83 Incorporating one additional phenylethyl glycinamide subunit to 1 (EC(50) = 660 nM) w

84 homooligomers ranging from 3 to 20 (R)-N-(1-phenylethyl)glycine (Nrpe) monomers in length.

85 consisting of five para-substituted (S)-N-(1-phenylethyl)glycine residues, by NMR spectroscopy.

86 Steric effects from an N-phenylethyl group on the amide of the isoselenazolone an

87 ponding to that of native heme modified by a phenylethyl group, presumably arising from the reaction

88 uents at the 10-position (4'-chlorophenyl or phenylethyl groups), and a chlorine atom at the 7-positi

89 tep asymmetric synthesis of the C2-symmetric phenylethyl imidazolium ion (IPhEt) from p-toluidine and

90 thiation and asymmetric substitution of N-(2-phenylethyl)isobutyramide (2) with selected electrophile

91 that phenylmethyl isocyacyanate (PMITC) and phenylethyl isothiocyanate (PEITC) induced sustained c-J

92 We found that phenylethyl isothiocyanate (PEITC) was capable of induci

93 tive CLL cells were highly sensitive to beta-phenylethyl isothiocyanate (PEITC) with mean IC(50) valu

94 n NMBA-treated animals that consumed dietary phenylethyl isothiocyanate (PEITC), a constituent of cru

95 treatment and modulated by cotreatment with phenylethyl isothiocyanate (PEITC).

96 mib in combination with the ROS inducer beta-phenylethyl isothiocyanate efficiently inhibits the grow

97 Addition of beta-phenylethyl isothiocyanate, a natural compound capable o

98 (SKF10047), ditolylguanidine, and (+/-)-2-(N-phenylethyl-N-propyl)-amino-5-hydroxytetralin all inhibi

99 d that, whereas bromocriptine and (+/-)-2-(N-phenylethyl-N-propyl)amino-5-hydroxytetralin hydrochlori

100 re stimulated with bromocriptine, (+/-)-2-(N-phenylethyl-N-propyl)amino-5-hydroxytetralin hydrochlori

101 Substitution at the 1-position with 2-phenylethyl (or alkyl/olefinic groups) and at N-3 with h

102 the tetrahydropyrimidinones showed that the phenylethyl P1' substituent, the hydroxyl group, and the

103 The 3beta-[(4'-phenylethyl)phenyl]tropane-2beta-carboxylic acid methyl

104 ent of optically active, predominantly (R)-1-phenylethyl phosphite 7 (R/S = 97/3; 94% ee), at 35-40 d

105 Dimethyl 1-phenylethyl phosphite, 7, gives the photo-Arbuzov rearra

106 binofuranosylcytosine 5'-N-(1-carbomethoxy-2-phenylethyl) phosphoramidate (8a), and 1-beta-arabinofur

107 luoro-2'-deoxy-5'-uridyl N-(1-carbomethoxy-2-phenylethyl)phosphoramidate (5a), 5-fluoro-2'-deoxy-5'-

108 -31020028 (N-(4-(4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl)-3-fluorophenyl)-2- pyridin-3

109 ery that 5-(4-chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)iso xazole (36) is a nanomola

110 level on the open and bridged forms of the 2-phenylethyl radical are reported here together with acti

111 tions of the singlet prochiral 1-naphthoxy/1-phenylethyl radical pairs (radical-pair B) that are form

112 O present, 70% (100y, eq 3) of the initial 1-phenylethyl radicals, 14, from 8 combine with radicals 3

113 nding to ca. 19% of the potentially formed 1-phenylethyl radicals.

114 potency by changing the stereochemistry, the phenylethyl segment, the urea portion, and the 4-phenoxy

115 and a unique "basket" arrangement of (S)-N(1-phenylethyl) side chains encompassing a bound ethanol mo

116 The presence of a 2-phenylethyl substituent in 13b and 37a or a 2-methylphen

117 Tightly related 3-(1-phenylethyl)sulfanyl-4H-1,2,4-benzothiadiazine 1,1-dioxi

118 The oxidation of aryl 1-methyl-1-phenylethyl sulfides promoted by the nonheme iron(IV)-ox

119 (ET-OT) mechanism leading to aryl 1-methyl-1-phenylethyl sulfoxides accompanied by products derived f

120 Two diastereomers of N-alpha-phenylethyl-t-butylsulfinamide derived from (-)-(S)-alph

121 N-alpha-Phenylethyl-t-butylsulfinamide is a complicated system f

122 5-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-5-[2-phenylethyl)thio] -2H-pyran-2-yl)pentanoic acid and 12c,

123 one 1c (5,6-dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one) was modeled in the act